
NDRA Stock Forecast & Price Target
NDRA Analyst Ratings
Bulls say
ENDRA Life Sciences Inc. is poised for growth due to its innovative Thermo Acoustic Enhanced UltraSound (TAEUS) technology, which addresses a critical gap in the diagnosis and monitoring of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) affecting over one billion individuals worldwide. The company anticipates potential FDA approval within the next year, a key catalyst that could significantly enhance the stock's value based on net present value (NPV) analysis, indicating substantial upside potential. Furthermore, TAEUS is designed to improve the accuracy and cost-effectiveness of liver disease diagnoses and monitoring compared to existing technologies, positioning the company favorably in the healthcare market.
Bears say
ENDRA Life Sciences Inc reported a net loss of $1.6 million, resulting in an earnings per share (EPS) of $(2.10), which fell short of estimates. The company faces significant risks, including balance sheet and liquidity challenges, potential failures in clinical trials, regulatory approval hurdles, and obstacles in commercialization and reimbursement processes. Additionally, competition and broader macroeconomic factors may negatively impact investor sentiment towards biotech and medtech investments, contributing to a pessimistic outlook on the stock.
This aggregate rating is based on analysts' research of ENDRA Life Sciences and is not a guaranteed prediction by Public.com or investment advice.
NDRA Analyst Forecast & Price Prediction
Start investing in NDRA
Order type
Buy in
Order amount
Est. shares
0 shares